The Patent Finder

Proximagen Limited

8 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

Recorded as renamed to Benevolentai Cambridge Limited (2018)

2
Ending by 2030
Sep 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 19, 2026
    The maintenance fee for Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds (US 9,035,066) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
  • 1 fee due Dec 11, 2026
    The maintenance fee for Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) (US 10,316,034) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
  • 1 fee due Mar 3, 2027
    The maintenance fee for Compounds I (US 10,399,973) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
  • 1 fee due Apr 1, 2027
    The maintenance fee for Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors (US 10,428,066) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

PatentTitleStatus Expires Confidence
US 9,035,066Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,399,973Compounds I
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,155,761CXCR4 Receptor Antagonists
In force
 · Medium confidence
In forceMedium confidence
US 10,428,066Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,512,082Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,530,208Imidazo[4,5-c]pyridine Derived Ssao Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 9,991,624Modular plug connector
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,316,034Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO)
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 8: 58 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 31 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited